LYNBROOK, N.Y., Sept. 20,
2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:
BSTC), a biopharmaceutical company that originated and continues to
develop collagenase based-therapies with a first in class
collagenase-based product marketed as XIAFLEX® in
the U.S. and Xiapex® in Europe, today
announced that BioSpecifics' President, Tom
Wegman, will present a corporate overview at the upcoming
2017 Cantor Fitzgerald Global Healthcare Conference at 2:15 p.m. ET on Wednesday,
September 27, 2017 in New York,
NY. This is an updated time from what was previously
announced in a press release issued by the Company on September 5th, 2017.
A live audio webcast of each presentation can also be accessed
under the "Events and Presentation" tab in the Investors section of
the Company's website at www.biospecifics.com or at
http://wsw.com/webcast/cantor6/bstc. An archived replay of the
webcast will be available for 30 days after the live event
concludes.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for thirteen clinical indications
to date. Injectable collagenase is marketed as
XIAFLEX® in the U.S. for the treatment of
Dupuytren's contracture and Peyronie's disease by BioSpecifics'
partner, Endo International plc (Endo). XIAFLEX® is
also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease in Europe
and Australia. Endo is partnered with Sobi, Actelion and Asahi
Kasei for Dupuytren's contracture and Peyronie's disease outside
the U.S. The XIAFLEX research and development pipeline includes
several additional promising indications. BioSpecifics is managing
the development of XIAFLEX for uterine fibroids and is conducting a
Phase 1 clinical trial. For more information, please
visit www.biospecifics.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-conference-300522052.html
SOURCE BioSpecifics Technologies Corp.